Randomized Study of Aspirin Resistant Patients Undergoing Angioplasty

This study has been terminated.
(Sponsor support withdrawn)
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT00289601
First received: February 8, 2006
Last updated: July 19, 2007
Last verified: July 2007
  Purpose

This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive patients who are randomized to heparin with or without eptifibatide therapy during PCI. The primary objective of this study is to determine if the use of eptifibatide is associated with a significant difference in post-PCI myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times upper limit of normal [ULN]) within 24 hours of low-medium risk PCI in patients who are aspirin or non-responsive as determined by VerifyNow Aspirin and P2Y12 testing.


Condition Intervention Phase
Angioplasty
Drug: eptifibatide
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Research Evaluation to Study Individuals Who Show Thromboxane Or P2Y12 Receptor Resistance

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • The primary endpoint is the incidence of myonecrosis, defined as an elevation in creatinine kinase – myocardial band (CK-MB) > 2 x IU/ml above the institution’s upper limit of normal within 24 hours following low-medium risk PCI.

Secondary Outcome Measures:
  • Incidence of CK-MB elevation >3x ULN
  • Incidence of CK-MB elevation to 3-5x ULN
  • Incidence of CK-MB elevation >5x ULN
  • Incidence of troponin I > 0.1ng/ml
  • MACE rates reported at discharge, 30 days and 6 months. (MACE is defined as a composite endpoint of death, MI, ischemic (non-hemorrhagic) stroke, and urgent target vessel revascularization)
  • Rate of bail-out use of eptifibatide/placebo.

Estimated Enrollment: 1200
Study Start Date: March 2006
Estimated Study Completion Date: December 2007
Detailed Description:

The primary objective of this study is to determine if the use of eptifibatide is associated with a significant difference in post-PCI myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times upper limit of normal [ULN]) within 24 hours of low-medium risk PCI in patients who are aspirin or clopidogrel non-responsive as determined by VerifyNow Aspirin and P2Y12 testing.

Secondary study objectives will include an assessment of safety. These safety determinations will be determined by monitoring the rates of MACE (defined as death, MI, ischemic [non-hemorrhagic] stroke and urgent revascularization by repeat PCI or CABG), bleeding events, rate of bailout procedures performed, elevations of CK-MB ratio (in the range of 3 to 5 times ULN and greater than 5 times ULN) and elevations of troponin I.

This study is a randomized, double-blind, multi-center study designed to compare differences in rates of myonecrosis (measured as an elevation of CK-MB ratio ≥ 2 times ULN) within 24 hours following low-medium risk percutaneous coronary intervention (PCI) in aspirin or clopidogrel non-responsive patients who are randomized to heparin with or without eptifibatide therapy during PCI. All subjects must also be pretreated with clopidogrel (300-600 mg) at least 2 hours before PCI. Study subjects will be randomized to either eptifibatide and unfractionated heparin or unfractionated heparin and placebo. Study subject randomization in aspirin non-responsive patients will be stratified based upon clopidogrel responsiveness.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Patients with coronary artery disease will be eligible for the study. Inclusion criteria are:

Patient is 21 years or older. Patient is scheduled to undergo low-medium risk percutaneous coronary intervention in native coronary vessels.

Patient self-reports that he/she has received aspirin ≥ 81 mg at least 4 hours prior to study screening.

Patient is defined as aspirin non-responsive based upon results of the VerifyNow™ Aspirin test, defined as an aspirin reaction units (ARU) > 475.

Patient is defined as clopidogrel non-responsive based upon the results of the VerifyNow P2Y12 test, defined as less than 20% inhibition.

Patient will be treated with 300- 600 mg of clopidogrel at least two hours before the intervention.

All patients will provide written informed consent, and the study protocol will be approved by the IRB of the participating centers.

Patient is male, or is a non-pregnant female.

Exclusion Criteria:

Patient has a known allergic reaction to the study medication. Patient has been diagnosed with a myocardial infarction within the prior 7 days.

Patient has unstable angina, defined as dynamic, ischemic ECG changes (ST-segment elevation, ST-segment depression, or T-wave inversion) at rest.

Patient has rest pain with left bundle branch block. Note: In a patient with rest pain and abnormal ECG that is believed to be non-acute (i.e., STTW abnormalities secondary to LVH, digoxin, or prior remote infarction), a second electrocardiogram 30 min apart is required to establish that these changes are non-dynamic and not indicative of active ischemia.

The target lesion(s) is located in a venous bypass graft. The patient has a chronic occlusion (present for longer than 3 months). The target lesion(s) has visible thrombus (by angiography). The patient has had a suspected aortic dissection. Patient has left ventricular ejection (LVEF) < 30%. Patient was receiving oral anticoagulation therapy.

Patient received any of the following drugs during 7 days prior to enrollment:

  • any GP IIb/IIIa inhibitor
  • ticlopidine
  • dipyridamole
  • cilostazol (Pletal) Patient has received non-steroidal anti-inflammatory drugs (NSAIDS), or any steroidal drugs 24 hours prior to enrollment.

Patient has been diagnosed with any stroke within the prior 3 months. Patient has active bleeding or bleeding diathesis. Patient has experienced trauma or major surgery in the preceding month. Patient has severe, uncontrolled hypertension (systolic blood pressure of more than 180 mm Hg).

Patient’s creatinine > 2.0 mg/dl prior to PCI. Patient has a hemoglobin level of less than 10.0 g per deciliter or a hematocrit below 30 percent.

Patient has a platelet count of less than 100,000 per cubic millimeter or more than 600,000 per cubic millimeter.

Of note, patients on chronic clopidogrel will only be eligible for VerifyNow P2Y12 testing. Clopidogrel non-responsiveness in this group will be defined as < 20% inhibition

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00289601

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Brigham and Women's Hospital
Schering-Plough
Investigators
Principal Investigator: Daniel I Simon, MD University Hospital Case Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00289601     History of Changes
Other Study ID Numbers: RESISTOR
Study First Received: February 8, 2006
Last Updated: July 19, 2007
Health Authority: United States: Food and Drug Administration

Keywords provided by Brigham and Women's Hospital:
aspirin
clopidogrel
resistance
angioplasty
percutaneous coronary intervention
myocardial infarction

Additional relevant MeSH terms:
Eptifibatide
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 16, 2014